Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for MedImmune
in the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark MedImmune' s performance against key rivals in the ethical
pharmaceutical sector
- See how MedImmune will build on its Synagis success with the launch of
follow-on product Numax, which is set to drive growth over the forecast period
- Following the acquisition of MedImmune by AstraZeneca, evaluate the
contribution to the Anglo-Swedish company' s top-line figures from 2006 to 2012
View Cart
